Aligos Therapeutics, Inc. - Common stock — Quarterly Cash Flow (NASDAQ:ALGS) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 70.09 M150.7 M134.71 M109.76 M88.53 M64.56 M Total liabilities 99.07 M34.25 M32.84 M37.93 M34.99 M32.77 M Total equity -28.97 M116.44 M101.87 M71.83 M53.55 M31.79 M Total liabilities & shareholders' equities 70.09 M150.7 M134.71 M109.76 M88.53 M64.56 M Total debt —————— Net debt ——————

News

Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress

Aligos Therapeutics stock rises on Phase 2 HBV study progress

Aligos reports progress on Phase 2 hepatitis B drug study

Aligos therapeutics appoints James Hassard as chief commercial officer

Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline

Aligos reports synergistic weight loss effect with THR-β agonist

Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Aligos Therapeutics stock reaffirmed Buy at H.C. Wainwright

Tracking Baker Brothers Portfolio – Q2 2025 Update

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study